Items where Author is "Soysal, A."

Article

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of neurology, neurosurgery, and psychiatry. pp. 361-369. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA neurology. ISSN 2168-6157 (Electronic) 2168-6149 (Print) 2168-6149 (Linking)

(2024) Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom. Journal of Medical Economics. pp. 109-125. ISSN 1369-6998

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) How patients with neuromyelitis optica spectrum disorder accumulate disability. Multiple Sclerosis Journal. pp. 1158-1160. ISSN 1352-4585

(2024) Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. Journal of Neurology Neurosurgery and Psychiatry. p. 9. ISSN 0022-3050

(2024) Preserving neurological function in patients at high risk and low risk of aggressive MS. Multiple Sclerosis Journal. pp. 631-634. ISSN 1352-4585

(2024) A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. Journal of Neurology. p. 12. ISSN 0340-5354

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) External validation of a clinical prediction model in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 261-269. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2023) Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Frontiers in Neurology. p. 10. ISSN 1664-2295

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2023) Vascular comorbidities are associated with increased relapse rates in relapsing-remitting MS. Multiple Sclerosis Journal. pp. 84-86. ISSN 1352-4585

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Description of Multiple Sclerosis cohorts from the Middle East between 2009 and 2019. Multiple Sclerosis Journal. pp. 17-18. ISSN 1352-4585

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Early non-disabling relapses are associated with a higher risk of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 947-950. ISSN 1352-4585

(2022) Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Mult Scler. p. 13524585221084577. ISSN 1352-4585

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2021) Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 755-766. ISSN 1352-4585

(2021) Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Comput Methods Programs Biomed. p. 106180. ISSN 0169-2607

(2021) Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. CNS Drugs. ISSN 1172-7047

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2018) Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. Neurology. ISSN 0028-3878

(2017) The effect of disease-modifying treatments on conversion to secondary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 32-34. ISSN 1352-4585